Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.

Eur Radiol · 2023 · PMC10667391 · PMID 37368105

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Subgroup analysis showed a trend that persisted in longer PFS and OS benefits with combination therapy compared to the monotherapy group (Fig. 3 , 4 , and Fig.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.